Abstract Number: 1742 • 2012 ACR/ARHP Annual Meeting
A Novel Murine Model of B Cell-Mediated Proteinuria Suggests Cytokines Mediate Podocyte Injury
Background/Purpose: B cell depletion therapies have been efficacious in several glomerulopathies. The contributions of B cells to proteinuria and foot process effacement remain unknown. The…Abstract Number: 1743 • 2012 ACR/ARHP Annual Meeting
IL-5-Induced FasL+ Regulatory B Cells Are Inhibited by IL-4 and Cyclosporine
Background/Purpose: We previously identified a subset of regulatory B cells that express the apoptosis-inducing molecule Fas ligand (FasL), and reported that these B cells were…Abstract Number: 1744 • 2012 ACR/ARHP Annual Meeting
Regulatory B Cells Supress the Progression of Fatal Autoimmunity in Lupus-Prone Mice
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disorder characterized by the production of anti-nuclear antibodies (ANA) which form immune complexes and promote…Abstract Number: 1745 • 2012 ACR/ARHP Annual Meeting
Amelioration of Experimental Autoimmune Arthritis by Adoptive Transfer of Foxp3-Expressing Regulatory B Cells Is Associated with the Regulatory T Cell/T helper 17 cell Balance
Background/Purpose: Foxp3 is a key regulator of the development and function of regulatory T cells (Tregs), and its expression is thought to be T cell-restricted.…Abstract Number: 1746 • 2012 ACR/ARHP Annual Meeting
Semaphorin 3A Increases the Regulatory Characteristics of B-Regulatory Cells
Background/Purpose: Semaphorin3A (sem3A) and neuropilin-1 (NP-1), are important regulatory molecules, previously reported by us to play role in lupus glomerulonephritis. In a recent study we…Abstract Number: 1747 • 2012 ACR/ARHP Annual Meeting
Gemin5 Is a New Target of Autoantibodies That Are Produced in Tight Connection with Antibodies to Snrnps and Survival of Motor Neuron (SMN) Complex
Background/Purpose: Most targets of autoantibodies in systemic rheumatic diseases are multiprotein-nucleic acids complex. Small nuclear ribonucleoproteins (snRNPs, Sm and U1RNP), key functional components of the…Abstract Number: 1748 • 2012 ACR/ARHP Annual Meeting
Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies
Background/Purpose: Vaccinating SLE patients with influenza and pneumococcal vaccines is generally considered safe and effective. However, conflicting reports regarding the impact of vaccination on autoantibody…Abstract Number: 1749 • 2012 ACR/ARHP Annual Meeting
Targeting of CD22 by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation
Background/Purpose: CD22, a member of the sialic acid-binding immunoglobulin-like lectins (Siglec) family, is exclusively expressed on B cells at mature stage and is lost upon…Abstract Number: 1750 • 2012 ACR/ARHP Annual Meeting
Phosphoprotein Changes Induced with Epratuzumab, an Antibody Targeting CD22 On B Cells
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22 that is currently in phase III clinical trials in systemic lupus erythematosus (SLE) patients. CD22 is found…Abstract Number: 1751 • 2012 ACR/ARHP Annual Meeting
Effect of Repeated Infusions of Rituximab in Patients with Primary Sjögren’s Syndrome
Background/Purpose: To assess the safety and efficacy of repeated infusions of rituximab (RTX) in patients with primary Sjögren syndrome (PSS). Methods: Patients with PSS were…Abstract Number: 1752 • 2012 ACR/ARHP Annual Meeting
Depletion of CD4-Effector Memory T Cells and Clonally Expanded IgG4 Memory B Cells May Explain the Therapeutic Efficacy of Rituximab in IgG4-Related Disease: Studies Using Flow Cytometry and Single-Cell Sequencing
Depletion of CD4-effector memory T cells and clonally expanded IgG4 memory B cells may explain the therapeutic efficacy of rituximab in IgG4-related disease: Studies using…Abstract Number: 1753 • 2012 ACR/ARHP Annual Meeting
A Rheumatoid Factor Paradox: Inhibition of Rituximab-Induced Complement Dependent Cytotoxicity of B Cells
Background/Purpose: Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of IgG antibodies. It is found in ~80% of patients with rheumatoid…Abstract Number: 1754 • 2012 ACR/ARHP Annual Meeting
Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response
Background/Purpose: Autoreactive B lymphocytes are thought to play an important role in rheumatoid arthritis (RA). B-cell depletion therapy by rituximab (RTX) has shown that targeting…Abstract Number: 1755 • 2012 ACR/ARHP Annual Meeting
The Alternative ΔCD20 Transcript Variant Is Not Expressed in B Cells and Synovial Tissue From Patients with Rheumatoid Arthritis
Background/Purpose: determining predictive factors for response to biologics may help to select appropriate treatment in patients with RA. Rituximab (RTX) is a chimeric monoclonal antibody…Abstract Number: 1756 • 2012 ACR/ARHP Annual Meeting
Peripheral Blood B Cell Subsets and BAFF/APRIL Receptor Expression, Together with Circulating BAFF and APRIL Levels, Are Disturbed in Rheumatoid Arthritis but Not in Ankylosing Spondylitis
Background/Purpose: B cells play a critical role in systemic autoimmune disease and especially rheumatoid arthritis (RA). BAFF and APRIL are involved in B cell activation…